Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Bellevue Life Sciences Acquisition Corp. Common Stock
BLAC | US
10.94
USD0
0%
BLAC | US
About Bellevue Life Sciences Acquisition Corp. Common Stock
Sector
Financial Services
Industry
Shell Companies
Earnings date
30/06/2024
As of date
21/10/2024
Close
10.94
Open
10.94
High
10.94
Low
10.94
Bellevue Life Sciences Acquisition Corp. focuses on effecting a merger share exchange asset acquisition stock purchase recapitalization reorganization or similar business combination with one or more businesses or entities. The company intends to acquire companies in the healthcare industry. Bellevue Life Sciences Acquisition Corp. was founded in 2020 and is based in Bellevue Washington. Bellevue Life Sciences Acquisition Corp. operates as a subsidiary of Bellevue Global Life Sciences Investors LLC.
View LessBLAC | US
Risk
2.3
Sharpe
0
Luna's Score
60/100
Recommendation
Hold
Luna says (BLAC | US)
What's Working
Positive Momentum
Low 6-Month Volatility (<30%)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
What's not Working
Microcap (<300M USD)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
2.3%1 month
2.3%3 months
4.3%6 months
5.4%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
2.92
Debt to equity
0.10
Debt to assets
0.07
Ent. to EBITDA
-98.70
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-
MarketCap
44.21M
MarketCap(USD)
44.21M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-
Short ratio
0.04
Short perc.
0.01
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
0.51
Range1M
0.51
Range3M
0.54
Volumes: Market Activity
Rel. volume
0.00
Price X volume
1.14K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -98.70 | -454.74 | Expensive |
| Ent. to Revenue | - | 4.09 | - |
| PE Ratio | - | 54.12 | - |
| Price to Book | 2.92 | 2.34 | Expensive |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 4.28 | 20.69 | Lower Risk |
| Debt to Equity | 0.10 | 0.03 | Expensive |
| Debt to Assets | 0.07 | 0.14 | Cheaper |
| Market Cap | 44.21M | 1.21B | Emerging |
